Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 9
2004 6
2005 7
2006 12
2007 4
2008 11
2009 17
2010 12
2011 19
2012 17
2013 7
2014 13
2015 7
2016 9
2017 16
2018 9
2019 10
2020 13
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

189 results
Results by year
Filters applied: . Clear all
Page 1
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. Kamada T, et al. Among authors: sato e. Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26. Proc Natl Acad Sci U S A. 2019. PMID: 31028147 Free PMC article.
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: sato e. Immunity. 2020 Jul 14;53(1):187-203.e8. doi: 10.1016/j.immuni.2020.06.016. Epub 2020 Jul 7. Immunity. 2020. PMID: 32640259
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Saito T, et al. Among authors: sato e. Nat Med. 2016 Jun;22(6):679-84. doi: 10.1038/nm.4086. Epub 2016 Apr 25. Nat Med. 2016. PMID: 27111280
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.
Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, Liao X, Lonn E, Gerstein HC, Yusuf S, Brouwers FP, Asselbergs FW, van Gilst W, Anderssen SA, Grobbee DE, Kastelein JJP, Visseren FLJ, Ntaios G, Hatzitolios AI, Savopoulos C, Nieuwkerk PT, Stroes E, Walters M, Higgins P, Dawson J, Gresele P, Guglielmini G, Migliacci R, Ezhov M, Safarova M, Balakhonova T, Sato E, Amaha M, Nakamura T, Kapellas K, Jamieson LM, Skilton M, Blumenthal JA, Hinderliter A, Sherwood A, Smith PJ, van Agtmael MA, Reiss P, van Vonderen MGA, Kiechl S, Klingenschmid G, Sitzer M, Stehouwer CDA, Uthoff H, Zou ZY, Cunha AR, Neves MF, Witham MD, Park HW, Lee MS, Bae JH, Bernal E, Wachtell K, Kjeldsen SE, Olsen MH, Preiss D, Sattar N, Beishuizen E, Huisman MV, Espeland MA, Schmidt C, Agewall S, Ok E, Aşçi G, de Groot E, Grooteman MPC, Blankestijn PJ, Bots ML, Sweeting MJ, Thompson SG, Lorenz MW; PROG-IMT and the Proof-ATHERO Study Groups. Willeit P, et al. Among authors: sato e. Circulation. 2020 Aug 18;142(7):621-642. doi: 10.1161/CIRCULATIONAHA.120.046361. Epub 2020 Jun 17. Circulation. 2020. PMID: 32546049
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.
Tschiderer L, Seekircher L, Klingenschmid G, Izzo R, Baldassarre D, Iglseder B, Calabresi L, Liu J, Price JF, Bae JH, Brouwers FP, de Groot E, Schmidt C, Bergström G, Aşçi G, Gresele P, Okazaki S, Kapellas K, Landecho MF, Sattar N, Agewall S, Zou ZY, Byrne CD, Nanayakkara PWB, Papagianni A, Witham MD, Bernal E, Ekart R, van Agtmael MA, Neves MF, Sato E, Ezhov M, Walters M, Olsen MH, Stolić R, Zozulińska-Ziółkiewicz DA, Hanefeld M, Staub D, Nagai M, Nieuwkerk PT, Huisman MV, Kato A, Honda H, Parraga G, Magliano D, Gabriel R, Rundek T, Espeland MA, Kiechl S, Willeit J, Lind L, Empana JP, Lonn E, Tuomainen TP, Catapano A, Chien KL, Sander D, Kavousi M, Beulens JWJ, Bots ML, Sweeting MJ, Lorenz MW, Willeit P; Proof-ATHERO Study Group. Tschiderer L, et al. Among authors: sato e. Gerontology. 2020;66(5):447-459. doi: 10.1159/000508498. Epub 2020 Jul 1. Gerontology. 2020. PMID: 32610336
Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Doki Y, Wada H. Yamamoto K, et al. Among authors: sato e. Cancer Sci. 2020 Apr;111(4):1103-1112. doi: 10.1111/cas.14328. Epub 2020 Feb 18. Cancer Sci. 2020. PMID: 31981293 Free PMC article.
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. Ishihara M, et al. Among authors: sato e. Cancer Immunol Immunother. 2020 Apr;69(4):663-675. doi: 10.1007/s00262-020-02483-1. Epub 2020 Jan 24. Cancer Immunol Immunother. 2020. PMID: 31980914 Free PMC article. Clinical Trial.
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jäger E, Sakaguchi S. Sugiyama D, et al. Among authors: sato e. Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. doi: 10.1073/pnas.1316796110. Epub 2013 Oct 14. Proc Natl Acad Sci U S A. 2013. PMID: 24127572 Free PMC article.
189 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page